

U.S. National Drug Control Strategy: Health Care Reform and Electronic Health Records



Office of National Drug Control Policy

June S. Sivilli, Sr. Advisor
Office of Demand Reduction

ONDCP Mission

ONDCP seeks to foster healthy individuals
and safe communities by effectively leading
the Nation's effort to reduce drug use
and its consequences.



National Demand Reduction Priority Areas

1. Build National System of “Prevention Prepared Communities”
2. Train primary care to intervene early with emerging abuse
3. Improve and integrate addiction treatment into mainstream healthcare
4. Smart, safe management of drug-related offenders
5. Performance-oriented monitoring systems



Implications with Health Care Reform

- Train primary care to intervene early with emerging abuse
- Improve and integrate addiction treatment into mainstream healthcare



Electronic Health Records

ONDCP supports the development of Electronic Health Records that both includes necessary data on patients substance abuse disorders and associated services to ensure they receive the necessary care from providers.



Federal Partners

- Office of the National Coordinator for HIT
- Center for Medicaid Services



Electronic Health Records

ONC's Privacy and Security Tiger Team

-June 2010



Advisory Committee Meeting

Tiger Teams Recommendations

Aug. 12, 2010



Recommendations

Developed as they relate to information exchange and patient identifiable health information among known entities to meet Stage 1 of meaningful use –the requirements by which health care providers and hospitals will be eligible for financial incentives for using health information technology.



Recommendations

The Tiger Team makes its recommendations as an ongoing approach to privacy and security that is comprehensive and firmly guided by fair information practices, a well established rubric in law and policy.



Recommendations

- Use of third party providers in health information exchanges;
- Trust Frameworks sharing information between providers for treating patients;
- Patient consent and how its implemented;



Recommendations

- The ability of technology to support more granular patient consents - sharing some info excluding other;
- Additional recommendations with respect to exchange for Stage 1 of Meaningful use – treatment , quality reporting and public health reporting.



What's Next ?

- There is more work to be done.
- ASPE study on 'The Other Provider,' serving population using many systems most often.



What can the NIDA CLINICAL TRIALS NETWORK DO?

- Partner with FQHCs
- Test/evaluate some of the EHR software as it serves provider and patients needs while adhering to the requirements of the ONC and privacy laws.
- Make recommendations for future rules.



For More Information:

www.WhiteHouseDrugPolicy.gov

www.hhs.gov/healthit

